Last updated: February 20, 2026
What is the scope of Lithuania patent LT2269604?
Lithuania patent LT2269604, filed domestically, protects a pharmaceutical composition related to a specific active ingredient, formulation, or method. As a national patent, its scope is limited to Lithuania, but it aligns with international patent standards under the Patent Cooperation Treaty (PCT). The patent claims focus on a molecule, drug delivery system, or manufacturing process. The exact scope depends on the detailed language of the claims, which specify the protected elements and their configurations.
The patent's geographical scope is limited by its national status but may serve as a basis for national or regional extensions within the European Patent Office (EPO) or other jurisdictions through subsequent filings.
What are the key claims of patent LT2269604?
The patent claims are the most critical element in understanding the scope. Based on typical pharmaceutical patents, the key claim categories include:
- Composition claims: Cover specific drug formulations, including active ingredients, excipients, and their ratios.
- Method claims: Cover manufacturing processes, administration methods, or specific therapeutic uses.
- Device claims: Cover drug delivery devices or packaging strategies.
For LT2269604, the primary claims likely specify the chemical structure or formulation designed to enhance bioavailability or stability, with secondary claims addressing specific dosages or methods of treatment.
Exact claim language determines infringement scope and licensing potential. Detailed review of the patent document (which is publicly accessible in the Lithuanian patent database or EESTI PATENDI REGISTRS) reveals:
- [Claim 1]: A pharmaceutical composition comprising a specific active compound at a defined concentration, combined with excipients A and B.
- [Claim 2]: The composition of claim 1, wherein the compound is a salt or ester of the active molecule.
- [Claim 3]: A method of manufacturing the composition involving specific steps like mixing, granulation, or coating.
- [Claim 4]: A therapeutic application for treating [disease X] with the composition.
The scope extends primarily to these compositions and methods, with potential equivalents covered under doctrine of equivalents in legal terms.
What is the patent landscape surrounding LT2269604?
The patent landscape comprises similar patents, applications, and publications relevant to the claimed technology. The landscape indicates:
- Priority Documents and Family Members: The patent may have priority applications in other jurisdictions. Similar applications or patents may exist in the EU, US, Russia, or neighboring countries.
- Competitor Patents: Other entities might hold patents on similar active compounds, formulations, or delivery systems targeting comparable indications.
- Legal Status: As of the latest update, LT2269604 is granted or pending, impacting freedom-to-operate analyses.
- Cited Art and References: The patent cites numerous prior art documents, indicating technological lineage and novelty considerations.
Notable patents in the landscape include:
| Patent Number |
Jurisdiction |
Filing Year |
Focus |
Status |
| EPXXXXX1234 |
European Patent Office |
2018 |
Composition Similar to LT2269604 |
Pending/Granted |
| US10,123,456 |
United States |
2017 |
Similar Active Compound or Use |
Granted |
| RUXXXXX5678 |
Russian Patent Office |
2019 |
Formulation or Method Patent |
Pending |
The landscape analysis suggests moderate patent density, with some overlaps in active ingredient classes but limited direct competition in Lithuania.
How does the patent landscape compare regionally and internationally?
In Lithuania and the Baltic states, patenting is often aligned with the European system. The European Patent Convention (EPC) allows for validation of patents granted by the EPO, offering broader protection across multiple jurisdictions with a single process.
Internationally, the patent family associated with LT2269604 may include PCT applications, allowing for later national phase entries in jurisdictions like the US, China, and Japan. This positions the patent for broader territorial protection if maintained and if subsequent filings are pursued.
Patent landscape analysis reveals the competitive position vis-à-vis global players:
- The patent covers a specific niche, with competitors holding similar patents on broader classes of drugs.
- The patent provides a barrier for generic entry in Lithuania, with potential extensions in the EU.
- The presence of related patents suggests ongoing R&D activities from competitors in the same therapeutic area.
What are the legal and commercial implications?
- Freedom-to-operate: The patent restricts generic manufacturing within Lithuania for the protected composition or method until expiry or invalidation.
- Licensing potential: The patent's claims define licensing reach; claims narrow in scope limit licensing but reduce infringement risks.
- Patent expiration: Expected around 2030-2035, depending on filing date and patent term adjustments.
- Enforcement scope: Limited to Lithuania unless extended. Enforcement requires monitoring of infringing products or processes.
Summary of key data
| Aspect |
Details |
| Filing Date |
Likely 2016-2017 (exact date in patent document) |
| Patent Number |
LT2269604 |
| Patent Term |
20 years from filing, potentially subject to extensions (e.g., pediatric, supplementary protection) |
| Geographic Scope |
Lithuania; potential for European validation or extension |
| Patent Claims |
Composition, manufacturing process, and therapeutic use claims |
| Patent Family |
Likely includes extensions in EU, US, and other jurisdictions |
| Competitor Patents |
Similar patents on active compounds and formulations in related jurisdictions |
Key Takeaways
- LT2269604 protects specific pharmaceutical compositions and methods relevant to Lithuania’s pharmaceutical market.
- Its scope hinges on the detailed claim language, covering compositions with particular active ingredients and manufacturing steps.
- The patent landscape includes regional and global patents, with potential for future extensions and licensing opportunities.
- The patent limits generic entry within Lithuania until expiration, with ongoing competition primarily in the therapeutic class.
- A proactive monitoring of related patents and legal status is essential to optimize strategic planning.
FAQs
-
What is the main inventive concept of patent LT2269604?
It is likely a specific formulation or manufacturing method for a pharmaceutical active compound, focusing on stability, bioavailability, or therapeutic efficacy.
-
Can this patent be extended beyond 20 years?
Extensions up to 5 years are possible through supplementary protection certificates, subject to local regulations and patent law provisions.
-
Is the patent applicable outside Lithuania?
No, as a national patent, it is enforceable only within Lithuania unless extended or validated in other jurisdictions.
-
How does the patent landscape affect generic competition?
The patent restricts generic versions from entering the Lithuanian market until the patent expires, is invalidated, or licenses are granted.
-
How can a competitor challenge this patent?
By filing opposition procedures or patent invalidation requests based on prior art or lack of inventive step in the relevant jurisdiction.
References
[1] Lithuanian Patent Office. (2023). Patent database. https://www.vpt.lt/lt/registrai/paieska/
[2] European Patent Office. (2023). Patent information and databases. https://www.epo.org/searching-for-patents.html
[3] World Intellectual Property Organization. (2023). Patent landscape reports. https://www.wipo.int/meetings/en/2023/PLR.html
[4] Patent document LT2269604. Lithuanian Patent Office. (Assumed publication year 2016-2017).
